Mumbai, June 11 -- Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals, today announced the launch of Winlevi(R) (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V. (SIX: COPN) (Cosmo) in October 2025.

Published by HT Digital Content Services with permission from Capital Market....